Insulin initiation in India is often delayed due to fear of injections & pain, treatment complexity & adherence concerns. Awiqli promises to reduce no of injections from 365 a year to 52.
Scientists associated with Madras Diabetes Research Foundation (MDRF) find that it often presents with more severe beta-cell dysfunction and relatively less insulin resistance.
The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.
Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.
Doctors Without Borders says new class of drugs & insulin devices could be leading to ‘exorbitant corporate profiteering’. Study published in Journal of the American Medical Association.
Icodec has been touted as a therapy that could eliminate the need for daily or mealtime insulin injections for people with severe diabetes. It has not been approved by any country so far.
Danish pharmaceutical giant Novo Nordisk has said it is set to apply for regulatory approval of its once-a-week insulin drug, Icodec. Results of Phase-3 clinical trial shown 'promising results'.
In a seminal work, former military officers Lt. Gen. D.S. Hooda & Lt. Col. Pavithran Rajan put forth a framework to approach cognitive warfare, called Socio-Technical-Cognitive Battlespace.
India, China and Russia share more contradictions than congruence. Each has a different worldview, as also a different adversary. The rude fact is that BRICS is the most irrelevant of all such groupings.
COMMENTS